Genentech May Appeal Rejection Of Cabilly Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Patent and Trademark Office rejects Genentech’s ’415 patent following Supreme Court ruling permitting MedImmune to challenge its validity.
You may also be interested in...
Genentech/MedImmune Patent Case Could Spur Tighter Licensing Deals
Supreme Court ruling that MedImmune can challenge the validity of a patent it had licensed could also encourage generic firms to seek declaratory judgments.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.